Patient presents for management of type 2 diabetes mellitus.  The patient reports suboptimal glycemic control despite current therapy consisting of [mention current therapy, e.g., metformin 1000 mg twice daily, lifestyle modifications].  Patient's A1c is [insert A1c value].  Patient's weight is [insert weight] kg and BMI is [insert BMI].  Patient denies any history of pancreatitis, medullary thyroid carcinoma, or multiple endocrine neoplasia syndrome type 2.  Family history is significant for [mention relevant family history, e.g., type 2 diabetes, cardiovascular disease].  Review of systems is negative for nausea, vomiting, diarrhea, and abdominal pain.  Physical exam unremarkable.  Diagnosis of type 2 diabetes mellitus confirmed.  Treatment goals discussed, including improved glycemic control, weight management, and reduction of cardiovascular risk factors.  Benefits and risks of Ozempic therapy, including potential side effects such as nausea, vomiting, diarrhea, constipation, and rare but serious adverse events like pancreatitis, were thoroughly explained to the patient.  Patient expresses understanding and agrees to initiate Ozempic 0.25 mg subcutaneously once weekly, titrating dosage as tolerated and based on clinical response and A1c levels.  Patient education provided regarding proper injection technique, medication storage, and potential side effects.  Follow-up appointment scheduled in four weeks to monitor efficacy, assess for adverse events, and adjust therapy as needed.  ICD-10 code E11.9 for type 2 diabetes mellitus without complications documented.  CPT codes for diabetes management and medication administration documented as appropriate.  Patient counseling regarding diet, exercise, and self-monitoring of blood glucose emphasized.  Importance of adherence to medication regimen and follow-up appointments reinforced.